TrueCardium®: From Human Biology to Predictive Medicine

---

TrueCardium® is a patented human cardiac organoid platform that recreates key structural and functional properties of human heart tissue in vitro, enabling highly predictive assessment of cardiac safety, disease biology, and therapeutic response.

1. Predictive Accuracy: Validated using clinical compounds and investigational drug candidates, with strong concordance to known human cardiac outcomes.
2. Scalable & Reproducible: Designed for long-term functional studies and compatible with medium- to high-throughput screening workflows.
3. Animal-free and Xeno-free: A powerful alternative to traditional preclinical models that improves translational relevance while eliminating animal-derived components from organoid generation.

TrueCardium® is the only human cardiac organoid system that is vascularised, innervated, and incorporates mural, stromal and resident immune cell populations, enabling integrated evaluation of drug effects across all major cardiac cell types. By closely reflecting human cardiac tissue biology, the platform supports precise cardiotoxicity screening, advanced cardiovascular disease modelling and efficacy assessment.

TrueCardium® has supported regulatory decision-making at BfArM and the U.S. FDA as part of an integrated nonclinical pharmacology package enabling clinical entry of a novel chemical entity. Alongside peer-reviewed translational studies, this highlights the platform’s readiness to advance cardiac safety and efficacy determination.